Apimeds Pharmaceuticals US, Inc. (APUS)

Market price: $3.07

7 methods not shown

• EV / EBITDA: EBITDA is non-positive — an EBITDA multiple yields no meaningful enterprise value (loss-making at the EBITDA line)
• EV / Revenue: revenue unavailable — cannot form EV / Revenue
• EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
• P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
• P / B: the market prices this company far outside its sector's P / B range (its own multiple is 0.04 vs a sector band of 3.69–6.84) — a sector-average bar would be misleading here, so it is withheld
• DCF (FCFF): DCF input(s) unavailable (delta_nwc, revenue_cagr) — cannot build FCFF
• P / E — adjusted: adjusted_eps unavailable — cannot form P / E — adjusted

We can't value this company — not enough of the financial data our methods require is available from its SEC filings.